Related Experiment Video
Updated: Mar 7, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Dilated cardiomyopathy
Robert G Weintraub1, Christopher Semsarian2, Peter Macdonald3
1Department of Cardiology, Royal Children's Hospital, Melbourne, VIC, Australia; Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
Insights
Dilated cardiomyopathy involves enlarged left ventricles and poor pumping function, often caused by genetics or acquired factors. Treatment focuses on managing heart failure symptoms and preventing sudden death.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Dilated cardiomyopathy (DCM) is characterized by left ventricular enlargement and impaired contractility.
- Genetic mutations (cytoskeletal, sarcomere, nuclear envelope proteins) cause up to 35% of DCM cases.
- Acquired causes include myocarditis, toxins, and metabolic/endocrine issues.
Purpose of the Study:
- To define dilated cardiomyopathy and outline its causes, symptoms, and current treatment strategies.
- To highlight the prognostic factors and emerging therapeutic investigations in DCM.
Main Methods:
- Review of existing literature on dilated cardiomyopathy.
- Analysis of genetic and acquired etiologies.
- Summary of clinical presentation, diagnostic indicators, and therapeutic interventions.
Main Results:
- DCM presents with symptoms of congestive heart failure, arrhythmias, or circulatory collapse.
- Prognosis is linked to ejection fraction and diastolic dysfunction severity.
- Standard treatments include ACE inhibitors and beta-blockers for chronic heart failure.
Conclusions:
- Effective management of dilated cardiomyopathy involves addressing heart failure, arrhythmias, and sudden death risk.
- Multidisciplinary care, device therapy, and advanced treatments like mechanical support or transplantation are crucial for refractory cases.
- Ongoing research explores preclinical disease treatment and stem cell therapy's potential role.
Abstract:
Dilated cardiomyopathy is defined by the presence of left ventricular dilatation and contractile dysfunction. Genetic mutations involving genes that encode cytoskeletal, sarcomere, and nuclear envelope proteins, among others, account for up to 35% of cases. Acquired causes include myocarditis and exposure to alcohol, drugs and toxins, and metabolic and endocrine disturbances. The most common presenting symptoms relate to congestive heart failure, but can also include circulatory collapse, arrhythmias, and thromboembolic events. Secondary neurohormonal changes contribute to reverse remodelling and ongoing myocyte damage. The prognosis is worst for individuals with the lowest ejection fractions or severe diastolic dysfunction. Treatment of chronic heart failure comprises medications that improve survival and reduce hospital admission-namely, angiotensin converting enzyme inhibitors and β blockers. Other interventions include enrolment in a multidisciplinary heart failure service, and device therapy for arrhythmia management and sudden death prevention. Patients who are refractory to medical therapy might benefit from mechanical circulatory support and heart transplantation. Treatment of preclinical disease and the potential role of stem-cell therapy are being investigated.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...

